{"id":941066,"date":"2026-03-02T12:33:47","date_gmt":"2026-03-02T17:33:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/"},"modified":"2026-03-02T12:33:47","modified_gmt":"2026-03-02T17:33:47","slug":"cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/","title":{"rendered":"CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BERKELEY HEIGHTS, N.J., March  02, 2026  (GLOBE NEWSWIRE) &#8212; CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\" style=\"max-width:25%;min-width:25%;vertical-align: top\">\n            <strong><br \/>\n              <em><br \/>\n                <u>Thursday, March 5<\/u><br \/>\n              <\/em><br \/>\n            <\/strong><br \/>\n            <u><br \/>\n              <strong><br \/>\n                <em><br \/>\n                  <sup>th<\/sup><br \/>\n                <\/em><br \/>\n              <\/strong><br \/>\n            <\/u><br \/>\n            <strong><br \/>\n              <em><br \/>\n                <u> @ 8:30am ET<\/u><br \/>\n              <\/em><br \/>\n            <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:25%;width:25%;min-width:25%;vertical-align: top\">Domestic:\u00a0\u00a0\u00a0<\/td>\n<td style=\"max-width:75%;width:75%;min-width:75%;vertical-align: top\">1-844-676-2922<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">International:\u00a0<\/td>\n<td style=\"vertical-align: top\">1-412-634-6840<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Webcast:\u00a0\u00a0\u00a0<\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"https:\/\/event.choruscall.com\/mediaframe\/webcast.html?webcastid=hEqBAf0u\" rel=\"nofollow\" target=\"_blank\">Webcast Link<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About CorMedix<\/strong>\n      <\/p>\n<p align=\"justify\">CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing <em>DefenCath<\/em><sup>\u00ae<\/sup> (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including <em>MINOCIN<\/em><sup>\u00ae<\/sup> (minocycline) for Injection, <em>REZZAYO<\/em><sup>\u00ae<\/sup> (rezafungin for injection), <em>VABOMERE<\/em><sup>\u00ae<\/sup> (meropenem and vaborbactam), <em>ORBACTIV<\/em>\u2122 (oritavancin), <em>BAXDELA<\/em><sup>\u00ae<\/sup> (delafloxacin), and <em>KIMYRSA<\/em><sup>\u00ae<\/sup> (oritavancin), as well as <em>TOPROL-XL<\/em><sup>\u00ae<\/sup> (metoprolol succinate).<\/p>\n<p align=\"justify\">CorMedix has ongoing clinical studies for <em>DefenCath<\/em> in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop <em>DefenCath<\/em> as a catheter lock solution for use in other patient populations. <em>REZZAYO<\/em> is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SjBN6Go6OFdL00ebqJWfLowFVXLZ197cyUPP_3K3PmrEPo3xw4OkqQrBStDsMAHndWS4TOoocdN-GCS71aq20wiUNZER2pM0aD1saT6t8D-faba7Ar1bcMyuDrUEnrCs7GQmZHUmRxkf3Alv62ZKhaj-dlznZYaBR6rWjSIrBlFGC5D1AwLcIzfKZrQyB4cojRKxjCPRPDgdN2pRWmtadiXc2cRIgvHHTR1sP8Qkf90=\" rel=\"nofollow\" target=\"_blank\">www.cormedix.com<\/a> or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iLCQJMYrZ9lUg3iBsLonyC_4VM93ir1W9e5AbP3HnusLE80CeTdFyo0IGkmiIRxW0-b-FUAHhsVBH9nO75DMKw==\" rel=\"nofollow\" target=\"_blank\">www.melinta.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Dan Ferry<br \/>Managing Director<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_3Ek1snPKQUMP8g_W5nHbKmBk4DRggHr7QkQVfv_T3w95nTcPtI5J6zX8MvM8sXuyMzz9LqctVlrBVZbDLmtXsqDncaGeqviSRvFp6QmIO0tsF46O9TgDf6thIVHcIft\" rel=\"nofollow\" target=\"_blank\">daniel@lifesciadvisors.com<\/a><br \/>(617) 430-7576<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzY4MCM3NDYxNzQ5IzUwMDA2NTY3OA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTQwNDE1ODktOTU2Ny00MmNkLWI4MDItZGNjMjU1ZTg1N2UwLTUwMDA2NTY3OC0yMDI2LTAzLTAyLWVu\/tiny\/CorMedix-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) &#8212; CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time. Thursday, March 5 th @ 8:30am ET Domestic:\u00a0\u00a0\u00a0 1-844-676-2922 International:\u00a0 1-412-634-6840 Webcast:\u00a0\u00a0\u00a0 Webcast Link \u00a0 \u00a0 About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath\u00ae (taurolidine and heparin) for the prevention &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-941066","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) &#8212; CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time. Thursday, March 5 th @ 8:30am ET Domestic:\u00a0\u00a0\u00a0 1-844-676-2922 International:\u00a0 1-412-634-6840 Webcast:\u00a0\u00a0\u00a0 Webcast Link \u00a0 \u00a0 About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath\u00ae (taurolidine and heparin) for the prevention &hellip; Continue reading &quot;CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T17:33:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzY4MCM3NDYxNzQ5IzUwMDA2NTY3OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026\",\"datePublished\":\"2026-03-02T17:33:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\\\/\"},\"wordCount\":288,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzY4MCM3NDYxNzQ5IzUwMDA2NTY3OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\\\/\",\"name\":\"CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzY4MCM3NDYxNzQ5IzUwMDA2NTY3OA==\",\"datePublished\":\"2026-03-02T17:33:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzY4MCM3NDYxNzQ5IzUwMDA2NTY3OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzY4MCM3NDYxNzQ5IzUwMDA2NTY3OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/","og_locale":"en_US","og_type":"article","og_title":"CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 - Market Newsdesk","og_description":"BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) &#8212; CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time. Thursday, March 5 th @ 8:30am ET Domestic:\u00a0\u00a0\u00a0 1-844-676-2922 International:\u00a0 1-412-634-6840 Webcast:\u00a0\u00a0\u00a0 Webcast Link \u00a0 \u00a0 About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath\u00ae (taurolidine and heparin) for the prevention &hellip; Continue reading \"CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-02T17:33:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzY4MCM3NDYxNzQ5IzUwMDA2NTY3OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026","datePublished":"2026-03-02T17:33:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/"},"wordCount":288,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzY4MCM3NDYxNzQ5IzUwMDA2NTY3OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/","name":"CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzY4MCM3NDYxNzQ5IzUwMDA2NTY3OA==","datePublished":"2026-03-02T17:33:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzY4MCM3NDYxNzQ5IzUwMDA2NTY3OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzY4MCM3NDYxNzQ5IzUwMDA2NTY3OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=941066"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941066\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=941066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=941066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=941066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}